Polyrizon Signs Non– Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments
“Our proprietary intranasal platform has the potential to enhance drug delivery bioavailability. We believe that intranasal delivery has the potential to improve patient outcomes by providing a ...
Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform
Raanana, Israel, March 13, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative ...
Polyrizon Ltd.: Polyrizon Signs Non- Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments
Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal ...
The Bakersfield Californian1d
Polyrizon Signs Non– Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for ...
Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced ...
Investing1d
Polyrizon sets date for annual shareholder meeting
Polyrizon Ltd., a pharmaceutical company specializing in preparations, has announced it will hold its Annual General Meeting (AGM) of Shareholders on Thursday, April 17, 2025. The meeting is ...
Polyrizon Ltd.: Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform
Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal ...
Investing2d
Polyrizon advances naloxone intranasal delivery studies
RAANANA, Israel - Polyrizon Ltd. (NASDAQ:PLRZ), a biotech firm in the development stage with a market capitalization of $2.95 million, is progressing in its preclinical studies for an intranasal ...
Nasdaq5d
Polyrizon Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&T Platform
Raanana, Israel, March 10, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative ...
Nasdaq3d
Polyrizon Ltd. Files Annual Report on Form 20-F for Fiscal Year 2024
Polyrizon's filing of its Annual Report on Form 20-F with the SEC reflects compliance with regulatory requirements, which can enhance the company's credibility and transparency to investors.
manilatimes5d
Polyrizon Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&T Platform
Raanana, Israel, March 10, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative ...
Investing5d
Polyrizon begins preclinical studies for nasal opioid overdose treatment
RAANANA, Israel - Polyrizon Ltd. (NASDAQ:PLRZ), a micro-cap biotech firm with a market capitalization of $3.46 million focused on developing nasal hydrogels, has launched preclinical studies for an ...